1/111
Looks like no tags are added yet.
MOA of obesity to insulin resistance
Obesity increases the number of adipocytes
The increase in adipocytes leads to: increased mass, chronic inflammation, hypoxia, oxidative stress, and ER stress
These factors lead to an increase in Adipocytokines TNF-a and IL-6 which lead to inflammation
These factors also decrease adiponectin which normally increases insulin sensitivity
Pancreas and BG levels - low BG
Pancreas senses low BG
Pancreas releases glucagon from alpha cells
In response to glucagon the liver turns glycogen into glucose
Glucose enters the blood to achieve normal BG
Pancreas and BG levels - high BG
Pancreas sense high BG
Pancreas releases insulin from beta cells
In response to insulin fat cells take glucose up from the blood
Glucose leaves the blood achieving normal BG
MOA of glucagon
Glucagon is released
It binds to glucagon receptor and activates AC
AC activates AMP making cAMP
Activates PKA
Increases Fructose 6-P from PEP
Increases glucose production
Insulin function
Insulin is necessary for metabolic homeostasis. Too much or too little systemic insulin is not healthy for the body from a metabolic standpoint.
Too much insulin
Will lead to promoted fat storage and eventually cause insulin resistance
Too little insulin
Results in hyperglycemia which can be very harmful to the body (damage nerves, blood vessels, tissues and organs)
Generally how does insulin lower BG
Stimulating peripheral glucose uptake especially by skeletal muscle and fat
Inhibiting hepatic glucose production
Insulin inhibits lipolysis in adipocytes, inhibits proteolysis and enhances protein synthesis. In other words it inhibits the liberation of fat cells as free fatty acids.
Insulin processing
Proinsulin is the prohormone precursor to insulin made in the beta cells of the islets of Langerhans, a specialized region of the pancreas. In humans proinsulin is encoded by the INS gene
MOA of insulin
When insulin binds to its receptor the Glut-4 receptor gets activated
Translocation of the glut-4 to the cell membrane occurs
The transporter is then able to take glucose from circulation and bring it into the cell
Once in the cell glucose can be used for cellular processes or converted into glycogen if it is not needed for immediate use
Glucose can also be converted into pyruvate which then gets converted into fatty acids which then gets converted to TGs and stored as fat.
What happens to insulin in T1D
No insulin is being produced. It can not bind to insulin receptor and stimulate glucose uptake or conversion of glucose to fatty acids
What happens to insulin in T2D
The skeletal muscle and adipose tissue become resistant to insulin. There is a decreased amount of signaling capacity for the IR. Glut-4 levels are decreased
Two pathways of insulin receptor
metabolic signals and growth signals
MOA of metabolic signals of insulin receptor
Insulin binds to its receptor activating IRS
IRS phosphorylates AKT
AKT triggers many things:
glucose uptake
Protein synthesis
Glycogen synthesis
Inhibits PEPC-K and IGF
MOA of growth signals of insulin receptor
Insulin binds to its receptor activating IRS and Shc
Shc drives ERK pathway
IRS activates p38 and JNK pathways
Associated with cell proliferation - important for cancer
Effect of glucagon in PEPC-K
Glucagon upregulates PEPC-K increasing glucose production in the liver
Rate limiting step of glucose synthesis
Oxaloacetic acid getting converted to PEP (phosphoenolpyruvate) via PEPC-K
Insulin effect on PEPC-K
Insulin downregulates PEPC-K decreasing glucose production in the liver
How does glucose production in the liver impact insulin resistance
If someone is insulin resistant, after they eat you do not want the liver to be making extra glucose when it doesn’t need to. This contributes to hyperglycemia.
MOA of injected insulin preparation
To mimic and stimulate insulin receptor signaling
Normal insulin structure
Monomer
Consists of alpha and beta chain
These chains can be modified to adjust duration of action
What form does insulin need to be in to interact with its receptor
Monomeric.
It can exist in dimeric and hexameric forms.
Short acting insulins tend to stay a monomer, while longer acting may be in hexamer or dimer forms
Rapid acting insulin types
Lispro
Aspart
Glulisine
Inhaled (Afrezza)
Short acting insulin types
Regular
Intermediate acting insulin types
NPH
Long acting insulin types
Glargine
Detemir
Degludec
Onset of rapid acting insulins
~15 minutes
Peak action of rapid acting insulins
~30 minutes - 1 hour
Duration of rapid acting insulins
3-4 hours
Onset of short acting insulin
~ 30 minutes
Peak action of short acting insulins
~2-3 hours
Duration of short acting insulins
~3-6 hours
Onset of intermediate acting insulins
~2-4 hours
Peak action of intermediate acting insulins
~6-10 hours
Duration of intermediate acting insulins
~10-16 hours
Onset of long acting insulins
30 minutes - 1.5 hours
Peak action of long acting insulins
no definitive peaks or ~8 hours for some
Duration of long acting insulins
~24 hours
Insulin lispro
First monomeric insulin analog
Recombinant human insulin
Equipotent to human insulin on a molar basis
Effect is more rapid and shorter in duration
What changes were made in insulin lispro
2 amino acids (Lys and Pro) near carboxyl terminal of the B chain have been reversed to make the insulin more monomeric
Lispro ADME
55-77% Bioavailability
Peak concentration in 30-90 minutes
Onset 5-15 minutes
Vdistribution is the same as insulin
SubQ dose has shorter t1/2
Insulin Aspart (Novolog)
Recombinant human insulin made in yeast
More rapid onset and shorter duration
Reduces monomer: monomer interaction between Pro-B-28 and Gly-B-23
What changes were made in insulin aspart
Proline amino acid was removed, aspartic acid was added at B-28 position
What changes were made in insulin Glulisine (Apidra
At B-3 position asparagine was replaced with lysine
At B-29 position lysine was replace with glutamic acid
Insulin Glulisine
Is a rapid acting insulin analogue that differs from human insulin in that the amino acids at B3 and B29 were replaced
It is similar to other rapid acting insulins
Given IV it has the same effect as regular insulin
Give SubQ is has more rapid onset but shorter duration that insulin
Novolin and Humulin R
Short acting
Effect appears within 30 minutes and peaks 2-3 hours after SubQ injection, generally lasting 5-8 hours
Formation of hexamers and dimers are important for its absorption
Difference in dissolution between IV and SubQ
IV: insulin is administered as hexamers and immediately dissolves to monomers
SubQ: Insulin is administered as hexamers and has to dissolve to dimers then monomers. Slower process
Novolin and Humulin N
Intermediate Acting
Not tested on, less used
Long acting insulins
Reaches the blood stream in 1-3 hours, does not peak and lasts for up to 24 hours
Levemir/Detemir
Ultra long acting
Reaches the long stream in 4-6 hours, does not peak, and lasts 24 hours or longer
Glargine/Lantus/Tujeo
Degludec/Tresiba
Insulin detemir
Long acting
Duration of action is 5.7-23.5 hours
Modification increases aggregation in sc tissue, thereby slows release from the tissues into systemic circulation
Reversible albumin binding
What changes were made in insulin determir
Terminal threonine is dropped from the B-30 position and myristic acid ist attached to there terminal B-29 lysine
Insulin Glargine
Duration of action is 24 hours
Soluble in acidic solution but precipitates in more neutral body pH after SubQ injection. The precipitate is then slowly released.
Has active M1 and M2 metabolites which have similar affinity for the insulin receptor
What changes were made in insulin glargine
2 arginine molecule are attached to the beta-chain carboxyl terminal and substitution of a glycine for asparagine at the A-21 position
Toujeo
An insulin glargine
Ultra long acting
Designed to slowly release small amounts of insulin for the gull 24 hours
Package in U-300 (lantus is U-100), lasts longer in the body
Insulin Degludec
Duration >42 hours
Formulated with hexadecanedioic acid, which allows the insulin to form soluble multi-hexamers once injected and results in a slower release of insulin into the bloodstream
Immunopathology of insulin preps
Insulin allergy
Allergy to non-insulin protein contaminants
Immune insulin resistance
Glucose infusion rate
Is a measure of how quickly the patient receives carbs, indirect measure of the insulin activity
Kinds of non-insulin anti diabetic agents
Biguanides
Thiazolidinediones
Incretin based therapies
SGLT2 inhibitors
Insulin Secretagogues
Metformin (Glucophage)
Widely used in treatment of T2D
T1/2 of 1.5-3 hours
Renally cleared, not metabolized or excreted by kidneys as active compound
Consider patient renal function
Functions of AMPK
AMP-activated protein kinase (AMPK) normally phosphorylates other proteins and modifies signaling/function. Metformin is an AMPK activator, it increases p-AMPK
Major effects of metformin
Decrease glucose production in the liver
Decrease glucose output via activation of the enzyme AMP-activates protein kinase (AMPK)
Minor Effects of metformin
Impairment of renal gluconeogenesis
Slowing of glucose absorption from the GI tract
Increased glucose to lactate conversion in enterocytes
Direct stimulation of glycolysis in tissues
Increased glucose removal from the blood
Adverse Effects of Metformin
Diarrhea - it increases intestinal motility, malabsorption
Vitamin B-12 deficiency
Lactic Acidosis
Metformin MOA via AMPK-P
Decreases conversion of lactate to pyruvate
Decreases production of lactate from glycerol
Down regulates PEPC-K
Decreases OAA formation
Enhances Glut4 expression and uptake of glucose into the muscle
Metformin action in the hepatocytes
AMPK phosphorylates things
Decreases PEPC-K mRNA and protein expression
Decreases G6P mRNA and protein expression (important for glucose production in liver)
Decreasing lactate to pyruvate conversion → decreasing OAA to PEP
Decreases glucose output from liver
What are incretins
Incretins are hormones found in the gut. They are secreted after nutrient intake and stimulate insulin secretion together with hyperglycemia. Stimulate release of insulin during a meal even before glucose levels rise.
GLP-1
Glucagon life protein is produced in L-cells of intestine.
Short ½ life of 1.5-5 minutes
GIP
Gastrin Inhibitory peptide, produced by K-cells of duodenum and ileum.
Short ½ life of 5-7 minutes
Main actions of Incretins
GLP-1 stimulates insulin release from the pancreas
GLP-1 inhibits glucagon release from the pancreas
DPP4
Inactivates GLP-1 by breaking it apart
DPP4 inhibitors
Block DPP4
Inhibit breakdown of GLP-1
Oral administration
Non selective and non-specific effects
Less side effects compared to GLP-1 agonists
Multiple actions of Incretins
Potentiation’s of glucose mediated insulin secretion
Suppression of postprandial glucagon release
Slowed Gastric emptying
Decreased Appetite
Possible increase in beta cell mass - anti-apoptotic role in beta cells
Forms of incretins
Analogs that mimic GLP-1
DPP4 inhibitors that inhibit GLP-1 breakdown
What causes the release of incretins
Glucose
Amino acids
Lipids
Where are incretin receptors located
Alpha and beta cells of the pancreas
Incretin Analogs
These drugs are analogues of GLP-1 and are designed to act like GLP-1
Modification to GLP-1 molecules alter half life and duration of action
Neurotransmission of the gut
Can also stimulate islet cells and release pancreatic secretions
GLP-1 Agonists vs DPP4 Inhibitors
More A1C reduction with GLP-1 Agonists
More effect on post prandial glucose with agonists
Delayed gastric emptying with glucose
Agonists effect satiety and weight loss
Agonists can cause dose related nausea and have potential CNS side effects
These effects are not seen with DPP4 inhibitors because they only work on an endogenous/normal amount of hormone

Exenatide (Byetta)
Synthetic analog of glucagon like polypeptide 1
Administered 2x/day
39 amino acid peptide
Peptidase resistant
T1/2 of 2.4 hours
1st incretin therapy, often used in conjunction with metformin or sulfonylureas
Bydureon
New formulation of Exenatide
Long acting release
Following a single dose exenatide is released over approximately 10 weeks from microspheres
Liraglutaide (Victoza)
Synthetic analog of GLP-1
Administered once a day
97% of amino acid homology to the endogenous GLP-1
Administered SQ as an isotonic solution
T1/2 is 13 hours
Has 16-C fatty acid moiety attached to it. This binds albumin and prolongs half life.
Dulaglutide (Trulicity)
Once a week
GLP-1 analogue
Has 3 substitutions and then fusion of the GLP-1 to a synthetic Ig4 Fc fragment
Very resistant to DPP4 degradation
T1/2 is 3.75-5 days
Lixisenatid (Adlyxin)
GLP-1 agonist
Administered once daily
C-terminal modification of the addition of 6 lysine residues and deletion of a proline
4x higher binding affinity for the GLP-1 receptor compared to native GLP-1
Considered short acting
T1/2 is 3 hours but its high affinity allows for daily dosing
Semaglutide (Ozempic)
Once weekly dosing
C-18 glutamic acid ADO linker which has affinity for human serum albumin which allows for long t1/2 of 7 days
Examples of DPP4 inhibitors
Gliptins
MOA of Gliptins
Work by blocking the action of DPP4 an enzyme that destroys incretins
AEs of incretins
nausea, diarrhea, and stomach pain
Flu-like symptoms HA, runny nose, sore throat
Skin reaction - red/purple rash
Joint pain
Which gliptins are renally cleared
Sitagliptin
Saxagliptin
Vildagliptin
Alogliptin
Need renal dose adjustments
Which gliptin is hepatically cleared
Linagliptin - does not need dose adjustment
Risk with SGLT2
UTI and yest infections
MOA of SGLT2i
SGLT2 normally works to take glucose from the urine in the proximal tubule and reabsorb it back into the kidney, increasing blood glucose.
SGLT2 inhibitors block this reabsorption and increase glucose excretion into the urine
Invokamet
Combination of Canagliflozin and metformin
Works to decrease glucose production and decrease sugar reabsorption
Synjardy
Combination of Empagliflozin and metformin
Decrease glucose production and decrease sugar reabsorption
Pioglitazone (Actos)
Thiazolidinedione
Thiazolidinediones
Peroxisome proliferator activated receptor gamma ligands (PPARy)
Enhance insulin sensitivity in peripheral tissues
Considered to be euglycemic → bring blood to normal range
PPARy
Nuclear receptor (moderates transcription) expressed in liver and adipocytes, as well as other tissues
Regulates fatty acid storage and glucose utilization (metabolism)
When PPARy is activated it stimulate pathways that improve insulin signaling
Makes tissues more responsive to insulin
Mainly work is adipose and skeletal muscle because they are the main victims of insulin resistance
Also decrease liver glucose output by improving the livers insulin resistance and turn off glucagon signaling to decrease glucose outpu
Thiazolidinediones/Glitazone MOA
When activated PPARy forms a heterodimer with RXR
bind to PPRE (response elements)
Changes gene transcription in cell nucleus
Net result is improved insulin sensitivity
AEs of thiazolidinediones
Adipocyte differentiation is modified which can lead to obesity
Leptin level increase leading to a decrease appetite
Some ILs decrease such as IL-6, could decrease inflammation in adipose tissue (Increase adiponectin levels)
Fluid retention
Pioglitazone activity
PPARa and PPARy activity
Metabolized by CYP3A4 and CYP2C8 into active metabolites
Also has TG lowering effects